[Skip to Content]
[Skip to Content Landing]
Views 539
Citations 0
Comment & Response
March 28, 2019

Notice of Retraction. Maret-Ouda et al. Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. JAMA Oncol. 2018;4(11):1576-1582

Author Affiliations
  • 1Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
  • 2School of Cancer Sciences, King’s College London, London, United Kingdom
JAMA Oncol. 2019;5(5):744-745. doi:10.1001/jamaoncol.2019.0653

On behalf of all coauthors, as principal investigator, I write to request retraction of the article, “Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries,”1 published online on August 23, 2018, and in the November 2018 issue of JAMA Oncology.

This article reports the results of a population-based cohort study that included 48 414 participants with gastroesophageal reflux disease (GERD) who underwent antireflux surgery and 894 492 participants with GERD treated with medication only in Denmark, Finland, Iceland, Norway, and Sweden. We concluded that the risk of esophageal adenocarcinoma decreased over time after antireflux surgery to reach a similar level as that in the background population and was similar when comparing individuals who underwent surgery with those who did not.

×